China Pharma Holdings (CPHI) Net Cash Flow (2010 - 2026)
China Pharma Holdings (CPHI) posted Net Cash Flow of -$134617.0 for Q1 2026, down 282.83% on a QoQ basis from $73631.0 in Q4 2025, and up 35.53% year-over-year from -$99323.1 in Q1 2025.
China Pharma Holdings (CPHI) Net Cash Flow (2010 - 2026) Analysis & Trends
China Pharma Holdings' Net Cash Flow history runs 17 years deep, the most recent figure standing at -$134617.0 for Q1 2026.
- Quarterly Net Cash Flow rose 35.53% year-over-year to -$134617.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$208814.0 (up 37.48% YoY) and the FY2025 annual result came in at -$283017.0, up 61.31% from the prior year.
- Net Cash Flow was -$134617.0 for Q1 2026 at China Pharma Holdings, down from $73631.0 in the prior quarter.
- Across five years, Net Cash Flow topped out at $463427.0 in Q3 2023 and bottomed at -$1.4 million in Q2 2022.
- A 5-year average of -$255334.4 and a median of -$65874.0 in 2024 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2023 — Net Cash Flow soared 9298.63% — and 2025, when it plunged 1194.31%.
- China Pharma Holdings' Net Cash Flow stood at -$60201.0 in 2022, then jumped by 105.86% to $3528.0 in 2023, then plunged by 905.33% to -$28412.0 in 2024, then jumped by 359.15% to $73631.0 in 2025, then plunged by 282.83% to -$134617.0 in 2026.
- Business Quant data shows CPHI's Net Cash Flow at -$134617.0 in Q1 2026, $73631.0 in Q4 2025, and -$399799.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 202.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -526.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 711.50 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -277.40 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 461.90 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -446.50 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -112.00 Mn |
| 10 | China Pharma Holdings | 629,344.02 | 460,870.02 | 285,487.00 | -134,617.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -134,617.00 |
| Mar 31, 2026 | -134,617.00 |
| Dec 31, 2025 | 73,631.00 |
| Dec 31, 2025 | 73,631.00 |
| Sep 30, 2025 | -399,799.00 |
| Sep 30, 2025 | -399,799.00 |
| Jun 30, 2025 | 251,971.00 |
| Jun 30, 2025 | 251,971.00 |
| Mar 31, 2025 | -208,820.00 |
| Mar 31, 2025 | -208,820.00 |
| Dec 31, 2024 | -28,412.00 |
| Dec 31, 2024 | -28,412.00 |
| Sep 30, 2024 | -30,889.00 |
| Sep 30, 2024 | -30,889.00 |
| Jun 30, 2024 | -65,874.00 |
| Jun 30, 2024 | -65,874.00 |
| Mar 31, 2024 | -578,302.00 |
| Mar 31, 2024 | -578,302.00 |
| Dec 31, 2023 | 3,528.00 |
| Dec 31, 2023 | 3,528.00 |